Adrenergic beta-antagonist: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Robert Badgett
Line 13: Line 13:
==Classification==
==Classification==
Generically available beta-blockers include:<ref name="pmid15912125">{{cite journal |author= |title=Drugs for hypertension |journal=Treat Guidel Med Lett |volume=3 |issue=34 |pages=39–48 |year=2005 |month=June |pmid=15912125 |doi= |url=http://www.medicalletter.org/scripts/articlefind.cgi?issue=34&page=39 |issn=}}</ref><ref name="pmid18323772">{{cite journal |author= |title=Nebivolol (Bystolic) for hypertension |journal=Med Lett Drugs Ther |volume=50 |issue=1281 |pages=17–9 |year=2008 |month=March |pmid=18323772 |doi= |url=http://www.medicalletter.org/scripts/articlefind.cgi?issue=1281&page=17 |issn=}}</ref>
Generically available beta-blockers include:<ref name="pmid15912125">{{cite journal |author= |title=Drugs for hypertension |journal=Treat Guidel Med Lett |volume=3 |issue=34 |pages=39–48 |year=2005 |month=June |pmid=15912125 |doi= |url=http://www.medicalletter.org/scripts/articlefind.cgi?issue=34&page=39 |issn=}}</ref><ref name="pmid18323772">{{cite journal |author= |title=Nebivolol (Bystolic) for hypertension |journal=Med Lett Drugs Ther |volume=50 |issue=1281 |pages=17–9 |year=2008 |month=March |pmid=18323772 |doi= |url=http://www.medicalletter.org/scripts/articlefind.cgi?issue=1281&page=17 |issn=}}</ref>
* Betaxolol
* Acebutolol
* [[Bisoprolol]]
* Nadolol
* Nadolol
* [[Propranolol]]
* [[Propranolol]]

Revision as of 01:15, 7 January 2009

This article is developed but not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Adrenergic_beta-antagonist&printable=yes
This editable, developed Main Article is subject to a disclaimer.

Adrenergic beta-receptor blockaders (beta-blockers) are "drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety".[1]

Beta-blockers vary within the class regarding their properties. Beta-blockers that have low intrinsic sympathomimetic activity (ISA), low membrane stabilizing activity, high beta 1-selectivity, and high lipophilicity may be more effective.[2]

Pharmacogenomics

Regarding the treatment of heart failure, there is conflicting evidence whether beta-blockers are as effective in African-American patients as in Anglo patients.[3] This may be due to a polymorphism in African-American patients of the G-protein-coupled receptor kinase (GRK5) (OMIM) that confers a natural "genetic beta-blockade".[4]

Variation adrenergic receptor genotype may also influence effectiveness.[5]

Beta-blockers such as metoprolol that are metabolized by cytochrome P-450 2D6 allele and may have more drug interactions[6] and inherited variations in metabolism.[7]

Classification

Generically available beta-blockers include:[8][9]

Cardioselective / beta 1-selectivity

Generic beta-blockers with beta 1-selectivity:[8][10]

Non-generic:

  • Betaxolol

Non-selective

Non-selective drugs include propranolol, timolol, nadolol, pindolol, penbutolol, and carteolol.

Intrinsic sympathomimetic activity

Generic beta-blockers with intrinsic sympathomimetic activity (less resting bradycardia and lipid changes):[8]

  • Acebutolol
  • Pindolol

Non-generic:

  • Penbutolol

Beta-blockers with alpha blocking activity

Generic beta-blockers with alpha blocking activity (more orthostatic hypotension):[8]

Clinical uses

The individual beta-blockers have been compared in the treatment of various diseases.[11]

Coronary heart disease

For more information, see: Coronary heart disease.

A meta-analysis has concluded that metoprolol may be the best beta-blocker for secondary prevention of myocardial infarction.[2]

Heart failure

For more information, see: Heart failure.

Two cohort studies suggest that atenolol and carvedilol may be more effect than metoprolol for the treatment of heart failure.[12][13]

References

  1. ↑ Anonymous (2024), Adrenergic beta-antagonist (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ 2.0 2.1 Soriano JB, Hoes AW, Meems L, Grobbee DE (1997). "Increased survival with beta-blockers: importance of ancillary properties". Prog Cardiovasc Dis 39 (5): 445–56. PMID 9122425. [e]
  3. ↑ Shekelle PG, Rich MW, Morton SC, et al (2003). "Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials". J. Am. Coll. Cardiol. 41 (9): 1529–38. PMID 12742294. [e]
  4. ↑ Liggett, Stephen B et al. 2008. A GRK5 polymorphism that inhibits [beta]-adrenergic receptor signaling is protective in heart failure. Nat Med advanced online publication. http://dx.doi.org/10.1038/nm1750 (Accessed April 29, 2008).
  5. ↑ Zaugg M, Bestmann L, Wacker J, et al (July 2007). "Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up". Anesthesiology 107 (1): 33–44. DOI:10.1097/01.anes.0000267530.62344.a4. PMID 17585213. Research Blogging.
  6. ↑ Onalan O, Cumurcu BE, Bekar L (May 2008). "Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine". Mayo Clin. Proc. 83 (5): 595–9. PMID 18452693. [e]
  7. ↑ Nozawa T, Taguchi M, Tahara K, et al (November 2005). "Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol". J. Cardiovasc. Pharmacol. 46 (5): 713–20. PMID 16220080. [e]
  8. ↑ 8.0 8.1 8.2 8.3 (June 2005) "Drugs for hypertension". Treat Guidel Med Lett 3 (34): 39–48. PMID 15912125. [e]
  9. ↑ (March 2008) "Nebivolol (Bystolic) for hypertension". Med Lett Drugs Ther 50 (1281): 17–9. PMID 18323772. [e]
  10. ↑ (January 2009) "Drugs for hypertension". Treat Guidel Med Lett 7 (77): 1–10. PMID 19107095. [e]
  11. ↑ Dean L (2007). “Comparing Beta Blockers”, PubMed Clinical Q&A. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. “Based on http://www.ohsu.edu/drugeffectiveness/” 
  12. ↑ Kramer JM, Curtis LH, Dupree CS, et al (December 2008). "Comparative effectiveness of beta-blockers in elderly patients with heart failure". Arch. Intern. Med. 168 (22): 2422–8; discussion 2428–32. DOI:10.1001/archinternmed.2008.511. PMID 19064824. Research Blogging.
  13. ↑ Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R (December 2008). "Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice". Arch. Intern. Med. 168 (22): 2415–21. DOI:10.1001/archinternmed.2008.506. PMID 19064823. Research Blogging.
Retrieved from "https://citizendium.org/wiki/index.php?title=Adrenergic_beta-antagonist&oldid=443259"